When evaluating a qualified DRI supplier for targeted cellular senescence assays, researchers must prioritize analytical precision, chemical purity, and lot-to-lot consistency. FOXO4-DRI (Forkhead box O4 D-retro-inverso peptide) is an essential research compound utilized in preclinical senolytic models. PX1 Research delivers laboratory-grade reagents verified via RP-HPLC and mass spectrometry, accompanied by lot-specific Certificates of Analysis and manufactured in ISO 17025 accredited US facilities.
When evaluating a qualified DRI supplier for targeted cellular senescence assays, researchers must prioritize analytical precision, chemical purity, and lot-to-lot consistency. FOXO4-DRI (Forkhead box O4 D-retro-inverso peptide) is an essential research compound utilized in preclinical senolytic models. PX1 Research delivers laboratory-grade reagents verified via RP-HPLC and mass spectrometry, accompanied by lot-specific Certificates of Analysis and manufactured in ISO 17025 accredited US facilities.
FOXO4-DRI is a modified, synthetic peptide designed to target the interaction between Forkhead box O4 (FOXO4) and the tumor suppressor protein p53. In non-senescent cells, p53 coordinates DNA repair and cell cycle arrest. However, in senescent cells—which accumulate during cellular aging or stressors—the persistent physical association of FOXO4 with p53 prevents normal apoptosis, driving secretome alterations known as the senescence-associated secretory phenotype (SASP). By altering this binding interface, FOXO4-DRI allows targeted apoptosis in senescent cell lines while sparing non-senescent healthy control cells in vitro.
The designation 'DRI' refers to D-retro-inverso modification, a peptidomimetic strategy where the L-amino acid sequence is reversed and replaced with D-amino acids. This architectural shift maintains the side-chain spatial orientation required for receptor target binding while imparting extraordinary resistance to proteolysis. As a result, researchers investigating senolytics research utilize FOXO4-DRI to assess cellular clearance mechanisms, metabolic shifts, and structural tissue remodeling in culture systems and animal models documented in the broader PX1 Research Library.
Identifying a trustworthy DRI supplier requires stringent verification of analytical processes, synthesis capabilities, and quality control systems. Because D-retro-inverso peptides feature complex stereochemistry and long amino acid chains, incomplete synthesis or sequence truncations can easily compromise assay reproducibility. Principle investigators should inspect vendor transparency, demanding third-party documentation for every individual lot prior to acquisition.
When auditing a potential vendor for FOXO4-DRI research reagents, review the following non-negotiable quality metrics: full structural confirmation by high-resolution mass spectrometry, purity determination exceeding 98% via reverse-phase high-performance liquid chromatography (RP-HPLC), strict endotoxin monitoring, and clear documentation of sequence fidelity. PX1 Research sets the benchmark for compliance by providing comprehensive analytical packets with every order, detailed thoroughly in our guide to peptide purity and analytical testing standards.
High-performance liquid chromatography is the industry gold standard for quantifying the chemical purity of synthetic peptides. When analyzing an RP-HPLC chromatogram from a DRI supplier, look for a single, sharp target peak with minimal baseline drift or adjacent secondary peaks. Secondary peaks often signify truncated sequences, deletion peptides, or residual protecting groups stemming from incomplete solid-phase peptide synthesis (SPPS). High-purity FOXO4-DRI should demonstrate a sharp, symmetrical peak reflecting greater than 98% integrated area.
Mass spectrometry (MS) provides the definitive mass-to-charge (m/z) verification needed to confirm peptide identity. Because FOXO4-DRI contains a specific arrangements of D-amino acids, mass spectrometry must confirm the exact monoisotopic or average molecular weight matching theoretical calculations. A reputable supplier supplies full-spectrum MS data showing clear parent ion peaks without persistent adducts or degradation fragments. Access our full catalog of structurally validated reagents via the all research peptides directory.
Bacterial endotoxins—primarily lipopolysaccharides (LPS) derived from Gram-negative cell walls—are potent cell culture contaminants capable of masking subtle biological phenotypes. In preclinical models, elevated endotoxin concentrations trigger inflammatory cascades, cytokine expression, and unspecific cytotoxicity, invalidating senolytic assay outcomes. A qualified DRI supplier must subject every lot to chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm low endotoxin limits (typically <0.01 EU/mg).
Furthermore, operational compliance requires synthesis and analytical evaluation to occur within cGMP-compliant or ISO 17025 accredited laboratory facilities. These certifications ensure that instrumentation undergoes routine calibration, analytical methods are validated against international standards, and sample handling minimizes environmental cross-contamination. PX1 Research manufactures all compounds domestically in compliant US facilities to guarantee uncompromising research consistency.
In cellular senescence studies, researchers frequently compare peptide-based interventions like FOXO4-DRI against small molecule senolytics and mitochondrial modulation agents. While FOXO4-DRI selectively disrupts p53-FOXO4 nuclear binding, small molecules act via distinct biochemical targets. For instance, combination treatments featuring Dasatinib research compounds inhibit tyrosine kinases, while flavanols such as Fisetin active reagents target anti-apoptotic Bcl-2 protein networks.
Additionally, Investigators frequently investigate senolytic mechanisms alongside mitochondrial membrane stabilization agents like SS-31 research peptide to differentiate targeted apoptotic mechanisms from broad metabolic optimization. Selecting the optimal research compound depends entirely on whether your assay targets selective senescent cell clearance, mitochondrial ROS attenuation, or broad-spectrum SASP suppression.
Proper reconstitution of FOXO4-DRI is necessary to ensure complete solubilization and prevent peptide aggregation. Because D-retro-inverso peptides contain complex hydrophobic regions, standard aqueous buffers like phosphate-buffered saline (PBS) may sometimes induce slow dissolution or micro-aggregation if added directly to dry lyophilized cake. Standard laboratory protocol recommends initial reconstitution in sterile, deionized water or a mild aqueous buffer (such as dilute sterile acetic acid), followed by gentle swirling.
Avoid vigorous vortexing or rapid mechanical agitation, as shear forces can introduce air bubbles and degrade complex peptide structures. Once dissolved, the stock solution may be diluted into sterile culture media or working buffers. Work strictly under a calibrated laminar flow hood using sterile, pyrogen-free pipette tips and microcentrifuge tubes to preserve reagent integrity during experimental setup.
Lyophilized FOXO4-DRI exhibits excellent long-term stability when stored under desiccation at -20°C to -80°C, isolated from light exposure. Upon receipt, laboratory personnel should inspect the sealed vial and place it immediately into climate-controlled freezer storage until experimental preparation begins.
Following reconstitution, liquid aliquots must be partitioned into single-use volumetric fractions to prevent repeated freeze-thaw cycles, which induce mechanical strain and cause peptide cleavage. Reconstituted stock solutions stored at -80°C maintain analytical stability for extended periods, whereas working solutions stored at 4°C should be utilized within standard short-term experimental windows.
Supply chain disruptions, extended international transit, and unverified customs clearance introduce severe risks to peptide degradation. Cold-chain breakdowns during overseas transit expose delicate research compounds to ambient thermal fluctuations. Procurement departments require a reliable domestic supply partner capable of providing complete lot traceability and accelerated distribution.
PX1 Research mitigates supply risks by managing centralized distribution facilities out of California and Arizona. Orders placed Monday through Friday ship same-day, arriving in specialized thermal packaging designed to protect compound stability. For institutional laboratories requiring bulk reserves or dedicated batch manufacturing, explore our streamlined wholesale laboratory accounts portal.
What factors define a qualified dri supplier for laboratory research?
A qualified DRI supplier provides lot-specific analytical documentation including RP-HPLC (>98% purity) and Mass Spectrometry, manufactures compounds in ISO 17025/GMP-compliant US facilities, performs LAL endotoxin testing, and offers cold-chain domestic shipping.
What analytical documentation should accompany FOXO4-DRI?
Every lot of FOXO4-DRI must include a third-party Certificate of Analysis (COA) containing RP-HPLC purity chromatograms, mass spectrometry molecular weight confirmation, and quantitative endotoxin test results.
Why is the D-retro-inverso modification significant in FOXO4-DRI?
The D-retro-inverso (DRI) modification reverses the amino acid sequence and replaces L-amino acids with D-amino acids. This configuration maintains the spatial orientation of side chains required for p53 binding while conferring high resistance to enzymatic proteolysis in vitro.
Why is endotoxin testing essential when evaluating a DRI supplier?
Bacterial endotoxins trigger non-specific inflammatory signaling and cellular toxicity. Quantitative LAL endotoxin testing ensures that biological responses observed in cell culture assays are attributable solely to FOXO4-DRI rather than bacterial contaminants.
How should lyophilized FOXO4-DRI be reconstituted for laboratory use?
FOXO4-DRI should be reconstituted under sterile conditions using pyrogen-free water or mild dilute acetic acid before diluting into working buffers. Avoid high-shear vortexing to prevent peptide denaturation.
What are the recommended long-term storage parameters for FOXO4-DRI?
Lyophilized FOXO4-DRI powder should be stored desiccated at -20°C to -80°C. Once reconstituted, stock solutions should be divided into single-use aliquots and stored at -80°C to eliminate freeze-thaw degradation.
How does FOXO4-DRI differ from non-peptide senolytics like Dasatinib?
FOXO4-DRI is a targeted peptide inhibitor designed to disrupt the specific FOXO4-p53 protein-protein interaction. In contrast, small molecules like Dasatinib or Fisetin act through kinase inhibition or cellular anti-apoptotic network modulation.
Can academic or commercial institutions procure bulk quantities of FOXO4-DRI?
Yes, verified academic institutions and research organizations can establish laboratory accounts for bulk procurement, custom synthesis, and recurring supply agreements via PX1 Research.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.